



Corporate Release No 427

28 February 2011

Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the Danish Securities Trading Act.

The list is based on reports received by H. Lundbeck A/S from the company's executives today or yesterday.

Name:	Egil Bodd
Job position of the executive:	Board member
Relation to executive (associated person or legal entity):	
ID code (ISIN code):	DK 0010287234
Description of the security:	Share
Nature of the transaction:	Sale of shares
Date of trading:	28 February 2011
Market on which the trading was effected:	Nasdaq OMX Copenhagen
Number of traded securities:	8,000 Shares
Market price of securities traded:	971,701 DKK

Persons/entities under an obligation to report

Persons or entities under an obligation to report are defined as members of the Executive Management and the Supervisory Board of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities means inter alia:

- spouse or cohabitant
- children below the age of 18
- legal entities in which the insider has a controlling influence



The content of this release will have no influence on the Lundbeck Group's financial expectations for 2011.

Lundbeck contacts

Investors:

Palle Holm Olesen
Chief Specialist, Investor Relations
+45 36 43 24 26

Magnus Thorstholm Jensen
Investor Relations Officer
+45 36 43 38 16

Jacob Tolstrup
Vice President
+1 847 282 5713

Media:

Mads Kronborg
Media Relations Manager
+45 36 43 28 51

Stine Hove Marsling
External Communication Specialist
+45 36 43 28 33

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2010, the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com.